Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Maxipime
(United States) [Available]Synonyms :
Class :
Antibiotics & Cephalosporins (fourth generation)
AdultÂ
Infusion solutionÂ
1g/50mlÂ
2g/100mlÂ
Powder for injectionÂ
1 gÂ
2 gÂ
Dosage Forms & StrengthsÂ
Infusion solutionÂ
1g/50mlÂ
2g/100mlÂ
Powder for injectionÂ
1 gÂ
2 g Â
Refer to adult dosingÂ
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
bazedoxifene conjugated estrogens
cefepime may reduce the therapeutic effects of oral forms of conjugated estrogen by altering gut microflora
cefepime will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
cefepime will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
furosemide may enhance the therapeutic effects of cefepime
the interaction may increase the therapeutic effects of cefepime
the interaction may increase the therapeutic effects of cefepime
cefepime reduces the therapeutic effects of sodium picosulfate by altering metabolism
cephalosporins may decrease serum concentration and enhance nephrotoxicity of aminoglycosides
enhance the serum drug concentration by reducing renal clearance
enhance the serum drug concentration by reducing renal clearance
may raise the risk of nephrotoxicity
cefepime increases the anticoagulant activity of warfarin by an unknown mechanism
it may diminish the excretion rate when combined with estradiol valerate resulting in a greater serum level
When loracarbef is used together with cefepime, the risk or seriousness of nephrotoxicity is enhanced
When cefepime is used together with piroxicam, this leads to increased risk or seriousness of nephrotoxicity
When cefmenoxime is used together with cefepime, this leads to enhanced risk or seriousness of nephrotoxicity
When cefepime is used together with proglumetacin, this leads to enhanced risk or seriousness of nephrotoxicity
When cefepime is used together with benoxaprofen, this leads to enhanced risk or seriousness of nephrotoxicity
cefepime leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefepime leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
cefepime leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefepime leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When cefepime is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
cefepime may decrease the excretion rate of almasilate, leading to higher serum levels
may enhance the adverse/toxic effect of rifampin
it may enhance the risk of nephrotoxicity when combined with phenylbutazone
the excretory rate of cefepime may be reduced when taken with mofebutazone, resulting in increased serum levels of cefepime
the rate of excretion of aurothioglucose may be reduced with cefepime
cefepime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefepime increases the serum concentration of other drugs by reducing renal clearance
cefepime increases the serum concentration of other drugs by reducing renal clearance
cefepime increases the serum concentration of other drugs by reducing renal clearance
the interaction reduces the effects of cefepime
cefepime increases the therapeutic effects of cyclopenthiazide
cefepime increases the serum concentration of other drugs by reducing renal clearance
cefepime will increase the effects of sulfasalazine
Penicillin-binding proteins (PBPs) are transpeptidases involved in the latter steps of peptidoglycan layer formation that are bound and inhibited by cefepime to cause disruption of bacterial cell walls.Â
In vitro, cefepime shows a wide range of action against both Gram-positive and Gram-negative bacteria.Â
Cefepime binds to PBP-2 in E. coli and Enterobacter cloacae, and PBP-3 and PBP-1 in Escherichia coli and Pseudomonas aeruginosa.Â
Frequency defined:Â Â
1-10%Â
Pruritis localized (1%)Â
Skin rash (1%)Â
Diarrhea (3%)Â
Nausea (2%)Â
Vomiting (1%)Â
Headache (1%)Â
Fever (1%)Â
Increase serum aspartate aminotransferase (2%)Â
Eosinophilia (2%)Â Â
<1%:Â
Local painÂ
Local inflammationÂ
VaginitisÂ
UrticariaÂ
Increased serum bilirubinÂ
Increased serum creatinineÂ
Anemia   Â
Postmarketing: (rare <1%)Â
Status epilepticusÂ
ComaÂ
HallucinationÂ
confusionÂ
NoneÂ
Contraindication:Â
Hypersensitivity to cefepime, penicillin, or other beta-lactam antibioticsÂ
Caution:Â
NeurotoxicityÂ
 Clostridioides difficileÂ
Nonconvulsive status epilepticusÂ
Pregnancy consideration: Cefepime is assigned under pregnancy category A. cefepime can be considered for the treatment of maternal infection.Â
Lactation: Cefepime can be excreted in breast milk. Monitor infants for GI disturbances such as diarrhea or thrush. Â
Pregnancy category:Â
The antibiotic cefepime belongs to the fourth generation of cephalosporins. It works against both Gram-positive and Gram-negative bacteria.Â
Cefepime is a good substitute for third-generation cephalosporins in the fight against bacteria because it is also a low inducer of type 1 beta-lactamases.Â
It is administered through intravenous route to infuse intermittently over 30 minutesÂ
Avoid administering with other drugs through Y-siteÂ
It is administered through intramuscular route with deep injectionÂ
Use IM route only in mild-to-moderate UTI cases due to E coli.Â
Patient information leafletÂ
Generic Name: CefepimeÂ
Pronounced: Se-fe-pimÂ
Why do we use cefepime?Â
Cefepime is recommended as an empirical treatment for individuals with febrile neutropenia and for the treatment of pneumonia caused by susceptible bacteria.Â
Cefepime is also recommended for the treatment of urinary tract infections (cUTI), both uncomplicated and complicated.Â